{
    "organizations": [],
    "uuid": "a7ecd053d0485f43c45d736760be59a453a6ef51",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-tg-therapeutics-announces-updated/brief-tg-therapeutics-announces-updated-results-from-the-ongoing-phase-2-study-of-ublituximab-idUSFWN1PS10A",
    "ord_in_thread": 0,
    "title": "BRIEF-TG Therapeutics Announces Updated Results From The Ongoing Phase 2 Study Of Ublituximab",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 2 (Reuters) - Tg Therapeutics Inc:\n* TG THERAPEUTICS, INC. ANNOUNCES UPDATED RESULTS FROM THE ONGOING PHASE 2 STUDY OF UBLITUXIMAB (TG-1101) IN PATIENTS WITH MULTIPLE SCLEROSIS AT THE THIRD ANNUAL ACTRIMS FORUM 2018\n* TG THERAPEUTICS INC - TG-1101 WAS WELL TOLERATED ACROSS ALL PATIENTS INCLUDING THOSE RECEIVING 1 HOUR INFUSIONS AT PHASE 3 DOSE Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-02T19:47:00.000+02:00",
    "crawled": "2018-02-03T21:29:22.001+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "tg",
        "therapeutic",
        "inc",
        "tg",
        "therapeutic",
        "announces",
        "updated",
        "result",
        "ongoing",
        "phase",
        "study",
        "ublituximab",
        "patient",
        "multiple",
        "sclerosis",
        "third",
        "annual",
        "actrims",
        "forum",
        "tg",
        "therapeutic",
        "inc",
        "well",
        "tolerated",
        "across",
        "patient",
        "including",
        "receiving",
        "hour",
        "infusion",
        "phase",
        "dose",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}